Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nanobiotix ( (NBTX) ) has shared an announcement.
On September 29, 2025, Nanobiotix announced updated Phase 1 results for their study on JNJ-1900 (NBTXR3) in combination with anti-PD-1 therapy for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC). The treatment demonstrated promising efficacy and safety, with high disease control and response rates in both anti-PD-1 naïve and resistant patients. The results suggest that JNJ-1900 (NBTXR3) could enhance local tumor control and potentially overcome resistance to immune checkpoint inhibitors, warranting further exploration in randomized controlled trials.
The most recent analyst rating on (NBTX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s stock score is primarily impacted by significant financial instability, marked by declining revenues and negative profitability. However, the stock’s strong technical momentum provides a counterbalance, suggesting potential short-term interest despite the company’s broader financial challenges. Valuation concerns persist due to the negative P/E ratio, reflecting non-profitability.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for cancer and other major diseases. The company focuses on developing JNJ-1900 (NBTXR3), a novel oncology product composed of functionalized hafnium oxide nanoparticles activated by radiotherapy, which has shown potential across various solid tumor indications.
Average Trading Volume: 31,840
Technical Sentiment Signal: Buy
Current Market Cap: $791.8M
For an in-depth examination of NBTX stock, go to TipRanks’ Overview page.